Absci (ABSI) Net Income towards Common Stockholders (2020 - 2026)

Absci (ABSI) reported Net Income towards Common Stockholders of -$29.6 million for Q1 2026, down 12.35% on a YoY basis from -$33.8 million in Q1 2025, and little changed sequentially from -$29.6 million in Q4 2025.

Absci (ABSI) Net Income towards Common Stockholders (2020 - 2026) Analysis & Trends

Absci (ABSI) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$29.6 million in Q1 2026.

  • For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 12.35% year-over-year to -$29.6 million; the trailing twelve-month figure through Mar 2026 stood at -$118.4 million (down 10.2% YoY), and the FY2025 full-year result was -$115.2 million, down 11.71% from the prior year.
  • Net Income towards Common Stockholders held at -$29.6 million in Q1 2026, from -$29.6 million in the prior quarter.
  • In the past five years, Net Income towards Common Stockholders ranged from a high of -$19.5 million in Q4 2022 to a low of -$41.7 million in Q2 2023.
  • A 5-year average of -$27.3 million and a median of -$27.4 million in 2024 frame the typical range for Net Income towards Common Stockholders.
  • Across the five-year window, Net Income towards Common Stockholders plunged 146.67% in 2022 and surged 40.61% in 2024, its largest moves.
  • Tracing ABSI's Net Income towards Common Stockholders over 5 years: stood at -$19.5 million in 2022, then dropped by 20.92% to -$23.5 million in 2023, then declined by 23.1% to -$29.0 million in 2024, then declined by 2.0% to -$29.6 million in 2025, then dropped by 0.13% to -$29.6 million in 2026.
  • Business Quant data shows ABSI's Net Income towards Common Stockholders at -$29.6 million in Q1 2026, -$29.6 million in Q4 2025, and -$28.7 million in Q3 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn - -625.73
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn - -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn - -14.46 Mn
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn 227.36 Mn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn 1.03 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn 727.20 Mn
7 Belite Bio 61.40 Bn 61.40 Bn - -0.68
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn 366.00 Mn
9 Revolution Medicines 37.37 Bn 37.37 Bn - -453.82 Mn
10 Absci 1.16 Bn 1.03 Bn - -29.60 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -29.60 Mn
Dec 31, 2025 -29.56 Mn
Sep 30, 2025 -28.71 Mn
Jun 30, 2025 -30.57 Mn
Mar 31, 2025 -26.35 Mn
Dec 31, 2024 -28.98 Mn
Sep 30, 2024 -27.40 Mn
Jun 30, 2024 -24.75 Mn
Mar 31, 2024 -21.98 Mn
Dec 31, 2023 -23.55 Mn
Sep 30, 2023 -21.99 Mn
Jun 30, 2023 -41.67 Mn
Mar 31, 2023 -23.36 Mn
Dec 31, 2022 -19.47 Mn
Sep 30, 2022 -27.26 Mn
Jun 30, 2022 -28.68 Mn
Mar 31, 2022 -29.49 Mn
Dec 31, 2021 -25.17 Mn
Sep 30, 2021 -23.88 Mn
Jun 30, 2021 -42.25 Mn